search
Back to results

Anti Inflammatory Treatment of Hypertension

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Levamlodipine
Amlodipine
Sponsored by
Affiliated Hospital of North Sichuan Medical College
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring Levamlodipine, Amlodipine, Serum inflammatory factors, Anti inflammatory treatment

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • ① In line with the diagnostic criteria of ISH2020 International Guidelines for Practice of Hypertension ② Age >18 years old, gender is not limited, during the treatment did not take other drugs that will affect blood pressure: such as antidepressants, oral contraceptives, Chinese herbal medicine, etc.; Voluntary participation and signing of informed consent, and can complete all the visit plan.

Exclusion Criteria:

  • (1) Those who do not want to take blood tests; (2) Left ventricular ejection fraction < 50%, heart rate <50 beats/min; ③ Acute coronary syndrome (unstable angina pectoris and myocardial infarction); ④ valvular heart disease, congenital heart disease, etc.; Other infectious diseases and malignant tumors; ⑥ Bronchial asthma; ⑦ Abnormal liver function and renal dysfunction (ALT BBB 0 80U/L, CR BBB 1 442mmol/L); Autoimmune diseases or any serious and fatal diseases; ⑨ Receiving lipid-lowering therapy and oral vitamins or antioxidants; They are mentally ill, have no self-awareness, and are unable to express themselves or cooperate with others.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Sham Comparator

    Arm Label

    Levamlodipine group

    Amlodipine group

    Arm Description

    Blood pressure lowering therapy with 2.5mg levamlodipine, plus metoprolol succinate

    To receive 5mg amlodipine to lower blood pressure, plus metoprolol succinate

    Outcomes

    Primary Outcome Measures

    After treatment, the blood pressure control of L-amlodipine group was better than that of amlodipine group
    the serum inflammatory factor level of L-amlodipine group was lower than that of amlodipine group
    Serum ATP level can be used to evaluate the anti-inflammatory effect of hypertension drugs

    Secondary Outcome Measures

    Full Information

    First Posted
    February 4, 2021
    Last Updated
    February 4, 2021
    Sponsor
    Affiliated Hospital of North Sichuan Medical College
    Collaborators
    First Hospitals affiliated to the China PLA General Hospital
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04740840
    Brief Title
    Anti Inflammatory Treatment of Hypertension
    Official Title
    Comparison of Anti-inflammatory Effects of Amlodipine and Levamlodipine in Patients With Hypertension
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    February 2021
    Overall Recruitment Status
    Completed
    Study Start Date
    May 1, 2010 (Actual)
    Primary Completion Date
    April 2, 2012 (Actual)
    Study Completion Date
    May 2, 2015 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Affiliated Hospital of North Sichuan Medical College
    Collaborators
    First Hospitals affiliated to the China PLA General Hospital

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    To investigate the anti-inflammatory effect of amlodipine and levamlodipine in the treatment of hypertension
    Detailed Description
    A total of 200 inpatients or outpatients in the Department of cardiovascular medicine of the third people's Hospital of Mianyang City from April 2021 to October 2021, who met the diagnostic criteria of ish2020 international hypertension practice guidelines, were selected and randomly divided into control group and experimental group, with 100 cases in each group. The control group was treated with amlodipine and the experimental group was treated with levoamlodipine. The changes of blood pressure and serum inflammatory factors were observed before and after treatment.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Hypertension
    Keywords
    Levamlodipine, Amlodipine, Serum inflammatory factors, Anti inflammatory treatment

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2, Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    Participant
    Allocation
    Randomized
    Enrollment
    200 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Levamlodipine group
    Arm Type
    Experimental
    Arm Description
    Blood pressure lowering therapy with 2.5mg levamlodipine, plus metoprolol succinate
    Arm Title
    Amlodipine group
    Arm Type
    Sham Comparator
    Arm Description
    To receive 5mg amlodipine to lower blood pressure, plus metoprolol succinate
    Intervention Type
    Drug
    Intervention Name(s)
    Levamlodipine
    Intervention Description
    According to the inclusion criteria of the trial, those who met the diagnosis of hypertension were randomly divided into the experimental group and the control group. The experimental group was treated with 2.5mg levamlodipine to lower blood pressure. Abdominal blood was emptying before the start of the trial and at the first and third month of medication.Data on CRP, TNF-α, IL-6, Lp-PLA2 and ATP were collected.
    Intervention Type
    Drug
    Intervention Name(s)
    Amlodipine
    Intervention Description
    According to the inclusion criteria, patients who met the diagnosis of hypertension were randomly divided into the experimental group and the control group. The experimental group was given 5mg amlodipine to lower blood pressure. Fasting blood was collected before the trial and during the first and third months of treatment. CRP, TNF-α, IL-6, Lp-PLA2 and ATP data were collected.
    Primary Outcome Measure Information:
    Title
    After treatment, the blood pressure control of L-amlodipine group was better than that of amlodipine group
    Time Frame
    One month after treatment
    Title
    the serum inflammatory factor level of L-amlodipine group was lower than that of amlodipine group
    Time Frame
    One month after treatment
    Title
    Serum ATP level can be used to evaluate the anti-inflammatory effect of hypertension drugs
    Time Frame
    One month after treatment

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: ① In line with the diagnostic criteria of ISH2020 International Guidelines for Practice of Hypertension ② Age >18 years old, gender is not limited, during the treatment did not take other drugs that will affect blood pressure: such as antidepressants, oral contraceptives, Chinese herbal medicine, etc.; Voluntary participation and signing of informed consent, and can complete all the visit plan. Exclusion Criteria: (1) Those who do not want to take blood tests; (2) Left ventricular ejection fraction < 50%, heart rate <50 beats/min; ③ Acute coronary syndrome (unstable angina pectoris and myocardial infarction); ④ valvular heart disease, congenital heart disease, etc.; Other infectious diseases and malignant tumors; ⑥ Bronchial asthma; ⑦ Abnormal liver function and renal dysfunction (ALT BBB 0 80U/L, CR BBB 1 442mmol/L); Autoimmune diseases or any serious and fatal diseases; ⑨ Receiving lipid-lowering therapy and oral vitamins or antioxidants; They are mentally ill, have no self-awareness, and are unable to express themselves or cooperate with others.

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Anti Inflammatory Treatment of Hypertension

    We'll reach out to this number within 24 hrs